商务合作
动脉网APP
可切换为仅中文
– Appointment Supports Immunic's Strategy to Build a Leading Multiple Sclerosis Organization Ahead of Potential Transition to Fully Integrated Commercial Company –
– 此项任命支持 Immunic 在潜在转型为完全整合的商业公司之前,打造领先的多发性硬化症组织的战略 –
NEW YORK
纽约
,
,
Oct. 19, 2026
2026年10月19日
/PRNewswire/ --
/美通社/ --
Immunic
Immunic
, Inc.
股份有限公司
(Nasdaq:
(纳斯达克:
IMUX
IMUX
), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Jaa Roberson as Chief People Officer (CPO), effective today. Ms. Roberson will report directly to Chief Executive Officer Erik Lundgren and will serve as a member of the executive leadership team..
),一家处于后期阶段的生物技术公司,致力于开创性地开发用于神经系统疾病的新型口服疗法,今日宣布任命Jaa Roberson为首席人力官(CPO),即日生效。Roberson女士将直接向首席执行官Erik Lundgren汇报,并担任执行领导团队成员。
The appointment represents another important step in Immunic's strategy to assemble a team of highly qualified leaders with key experience in building a leading multiple sclerosis (MS) organization. In this newly created executive role, Ms. Roberson will lead the company's global talent and organizational strategy, with a particular focus on attracting and developing the specialized capabilities required as Immunic prepares for its pivotal Phase 3 ENSURE read-out expected by the end of 2026, as well as potential regulatory filings and commercialization of vidofludimus calcium (IMU-838)..
此次任命是Immunic战略中的又一重要举措,旨在组建一支由具备构建领先多发性硬化症(MS)组织关键经验的高素质领导者组成的团队。在这一新设立的高管职位上,罗伯森女士将领导公司的全球人才与组织战略,重点在于吸引和培养所需的专业能力,以支持Immunic为预计于2026年底公布的关键性III期ENSURE研究结果、潜在的监管申报以及vidofludimus calcium(IMU-838)的商业化做好准备。
'Over the past several months, we have been assembling a leadership team with deep experience in MS and a track record of successfully developing and commercializing important therapies for patients,' said Erik Lundgren, Chief Executive Officer of Immunic. 'Our continued goal is to build an exceptional MS organization with the right people and capabilities in place.
“在过去几个月里,我们一直在组建一支在多发性硬化症(MS)领域拥有深厚经验、并具备成功开发和商业化重要患者疗法业绩的领导团队。”Immunic 公司首席执行官埃里克·伦德格伦表示。“我们的持续目标是打造一家卓越的 MS 专业机构,配备合适的人才和能力。”
I am thrilled that Jaa joins us at this critical time, with the pivotal Phase 3 data in relapsing MS expected by year-end and our progressive MS trial preparations advancing. Jaa will be a strategic partner on the management team helping us attract, develop, and retain world-class talent while building the structures, systems, and culture necessary for scaling from a research and development biotechnology company toward a fully integrated commercial organization.'.
我非常高兴 Jaa 在这一关键时刻加入我们的团队。预计年底前将公布复发型多发性硬化症(MS)的关键 III 期临床数据,同时我们的进展型 MS 临床试验准备工作也在稳步推进。Jaa 将成为管理团队中的战略伙伴,帮助我们吸引、培养和留住世界级人才,同时构建必要的架构、体系和文化,推动公司从一家研发型生物技术企业向全面整合的商业化组织转型。
'I am excited to join Immunic at such an important stage in the company's evolution,' said Jaa Roberson, Chief People Officer of Immunic. 'Immunic has assembled a strong leadership team with deep experience across MS research and development, regulatory and commercialization. With the pivotal Phase 3 data approaching, my focus will be on building the broader organization and continuing to attract the specialized talent, capabilities, and culture needed to support potential regulatory approval and commercialization, while preserving the agility and focus that differentiate Immunic as a biotechnology company.'.
“在公司发展的这一重要阶段加入Immunic,我感到非常兴奋。”Immunic首席人力官Jaa Roberson表示。“Immunic已组建了一支强大的领导团队,在多发性硬化症(MS)研发、监管事务及商业化方面拥有深厚的经验。随着关键的III期临床数据即将公布,我的工作重心将放在构建更广泛的组织架构,并持续吸引支持潜在监管审批和商业化所需的专业人才、能力和文化,同时保持使Immunic作为一家生物技术公司脱颖而出的敏捷性与专注度。”
Ms. Roberson is a people leader with more than two decades of human resources (HR) experience across the biopharma, health insurance, and retail industries, successfully leading companies through growth, transformation and change by building high performance, diverse and inclusive organizations where everyone thrives, contributes and grows to drive impactful patient and business outcomes.
罗伯森女士是一位拥有二十多年人力资源(HR)经验的人才领导者,其职业生涯横跨生物制药、健康保险和零售行业。她通过打造高绩效、多元化和包容性的组织,让每位员工都能蓬勃发展、贡献力量并实现成长,从而成功引领企业应对增长、转型与变革,推动产生深远影响的患者福祉和业务成果。
Most recently as Chief People Officer at Day One Biopharmaceuticals, she guided the organization to scale and grow from 37 to 200 employees while maintaining strong engagement and retention, successfully transition from clinical to commercial stage following the approval and launch of OJEMDA.
她最近担任Day One Biopharmaceuticals的首席人力官,带领公司从37名员工扩展至200名员工,同时保持了高水平的员工敬业度和留存率,并在OJEMDA获批及上市后成功实现了从临床阶段向商业化阶段的转型。
®
®
(pediatric low-grade glioma), expand the pipeline into adult oncology, which included the acquisition of Mersana Therapeutics, and ultimately Day One's acquisition by Servier. Previously, Ms. Roberson led HR at Bellicum Pharmaceuticals and at Achaogen, where she supported the companies' expansions, pre-commercial and commercial launch preparations, as well as restructuring and workforce transitions.
(儿科低级别胶质瘤),并将产品线拓展至成人肿瘤领域,其中包括收购 Mersana Therapeutics,以及最终 Day One 被 Servier 收购。此前,罗伯森女士曾在 Bellicum Pharmaceuticals 和 Achaogen 领导人力资源工作,支持这些公司的业务扩张、上市前准备及商业化发布准备,以及重组和员工过渡。
Earlier in her career, she spent six years at Genentech, a member of the Roche Group, as an HR Business Partner supporting commercial franchises, including the build of the Ocrevus.
在她职业生涯的早期,她曾在罗氏集团旗下的基因泰克公司担任人力资源业务合作伙伴,为期六年,负责支持包括奥克雷珠单抗(Ocrevus)上市筹备在内的商业产品线。
®
®
(MS) and Hemlibra
(MS) 和 Hemlibra
®
®
(hemophilia) franchises. She also held HR leadership roles of increasing responsibility at Blue Shield of California, Levi Strauss & Co. and Williams-Sonoma, Inc. Ms. Roberson holds a Bachelor of Arts from Rice University and a Master of Music in Violin Performance from the San Francisco Conservatory of Music..
(血友病)特许项目。她还在加州蓝盾、李维斯公司(Levi Strauss & Co.)和威廉姆斯-索诺玛公司(Williams-Sonoma, Inc.)担任过职责日益加重的人力资源领导职务。罗伯森女士拥有莱斯大学的文学学士学位,以及旧金山音乐学院的小提琴演奏音乐硕士学位。
The Compensation Committee of Immunic's Board of Directors granted Ms. Roberson an initial equity option to purchase 190,000 shares of common stock of the company under the Immunic, Inc. 2026 Inducement Equity Compensation Plan (the 'Options'). The Options were granted as an inducement material to Ms.
Immunic公司董事会薪酬委员会根据《Immunic, Inc. 2026年激励性股权补偿计划》授予Roberson女士一项初始股票期权,使其有权购买公司190,000股普通股(该“期权”)。该期权的授予构成对Roberson女士的重要激励。
Roberson's commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). The Options will be time vested, with 25% vesting on the one-year anniversary of October 19, 2026 and the remainder vesting on a monthly basis in 36 equal installments..
罗伯森根据纳斯达克上市规则5635(c)(4)开始任职。期权将按时间归属,25%在2026年10月19日的一周年纪念日归属,其余部分在36个月内按月等额分期归属。
About Immunic, Inc.
关于 Immunic, Inc.
Immunic, Inc. (Nasdaq:
Immunic, Inc.(纳斯达克:
IMUX
IMUX
) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials for the treatment of relapsing multiple sclerosis, with top-line data expected to be available by the end of 2026.
)是一家处于后期阶段的生物技术公司,致力于开创性地开发用于神经系统疾病的新型口服疗法。该公司的主要开发项目维多氟迪莫斯钙(IMU-838)目前正处于治疗复发型多发性硬化的三期临床试验评估阶段,预计将于2026年底前公布主要数据。
Initiation of an additional Phase 3 clinical trial in progressive MS is expected later in 2026. Vidofludimus calcium has already shown therapeutic potential and a favorable safety and tolerability profile in Phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases.
预计将于2026年晚些时候启动一项针对进展型多发性硬化的额外III期临床试验。维多氟迪莫斯钙已在复发缓解型多发性硬化、进展型多发性硬化及其他疾病的II期临床试验中展现出治疗潜力以及良好的安全性和耐受性特征。
Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). The company's development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases.
Vidofludimus calcium 通过其作为首创的核受体相关 1(Nurr1)激活剂的作用机制,发挥神经保护作用,同时通过选择性抑制二氢乳清酸脱氢酶(DHODH)产生额外的抗炎和抗病毒效应。该公司的研发管线还包括早期阶段的项目,如 IMU-381 和 IMU-856,旨在构建一个更广泛的治疗平台,以应对神经退行性疾病和自身免疫性疾病。
For further information, please visit: .
如需更多信息,请访问:。
www.imux.com
www.imux.com
.
。
Cautionary Statement Regarding Forward-Looking Statements
关于前瞻性陈述的警示性声明
This press release contains 'forward-looking statements' that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements.
本新闻稿包含根据1995年《私人证券诉讼改革法》所提供的“安全港”条款所定义的“前瞻性陈述”,这些陈述涉及重大风险和不确定性。除历史事实陈述外,本新闻稿中所有关于战略、未来运营、未来财务状况、未来收入、预计支出、现金及现金跑道充足性、预期时间安排、临床试验的开发与结果、前景、管理层的计划与目标的陈述均为前瞻性陈述。
Examples of such statements include, but are not limited to, statements relating to Immunic's development programs and the targeted diseases; the potential for Immunic's development programs to safely and effectively target diseases; preclinical and clinical data for Immunic's development programs; the feasibility of advancing vidofludimus calcium to a confirmatory Phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials, anticipated clinical milestones and regulatory approvals; the nature, strategy and focus of the company and further updates with respect thereto; the development and commercial potential of any product candidates of the company; expectations regarding the capitalization, resources and ownership structure of the company; and the executive and board structure of the company.
此类陈述的示例包括但不限于:与Immunic的研发项目及其靶向疾病相关的陈述;Immunic研发项目安全有效靶向疾病的潜力;Immunic研发项目的临床前和临床数据;将钙剂vidofludimus推进至进行性多发性硬化症确证性III期临床试验的可行性;当前及未来临床试验的时间安排、预期的临床里程碑和监管批准;公司的性质、战略和重点以及与此相关的进一步更新;公司任何候选产品的开发和商业潜力;对公司资本结构、资源和所有权结构的预期;以及公司的高管和董事会结构。
Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties.
Immunic 可能实际上无法实现前瞻性陈述中披露的计划、意图或达到预期或预测,您不应过度依赖这些前瞻性陈述。此类陈述基于管理层当前的预期,并涉及重大风险和不确定性。
Actual results and performance cou.
实际结果和表现。
www.sec.gov
www.sec.gov
or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release..
或访问 ir.imux.com/sec-filings。本新闻稿中作出的任何前瞻性陈述仅反映本新闻稿发布之日的情况。Immunic 否认有任何意图或义务更新这些前瞻性陈述,以反映在其作出之后发生的事件或情况。Immunic 明确声明,对于基于本新闻稿全部或部分内容而采取或不采取的任何行动,不承担任何责任。
Contact Information
联系方式
Immunic, Inc.
Immunic, Inc.
Jessica Breu
杰西卡·布鲁
Vice President Investor Relations and Communications
投资者关系与沟通副总裁
+49 89 2080 477 09
+49 89 2080 477 09
[email protected]
[email protected]
US IR Contact
美国投资者关系联系人
LifeSci Advisors
LifeSci 顾问
Joyce Allaire
乔伊斯·阿莱尔
[email protected]
[email protected]
US Media Contact
美国媒体联系人
Real Chemistry
真实化学
[email protected]
[email protected]
SOURCE Immunic, Inc.
来源:Immunic, Inc.
21
二十一
%
%
more press release views with
更多新闻稿浏览量,通过
Request a Demo
申请演示